SOUTH SAN FRANCISCO, Calif., June 01, 2016 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals Inc.® (NASDAQ:PTLA), today announced that it recently dosed the first patient in a Phase 2a study that is evaluating the safety and efficacy of cerdulatinib in patients with relapsed/refractory B-cell and T-cell malignancies who have failed multiple therapies. Cerdulatinib is an oral, dual Syk/JAK kinase inhibitor in development to treat patients with resistant or relapsed hematologic cancer. Cerdulatinib inhibits two key cell signaling pathways that promote cancer cell growth in certain hematologic malignancies.
Portola recently completed a Phase 1 study of cerdulatinib, which identified the maximum tolerated dose. Pharmacokinetic and pharmacodynamic outcomes data from the Phase 1 study will be presented in a poster session at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting 2016, which is taking place from June 3-7 in Chicago. Final results of the Phase 1 study, as well as data from two other cerdulatinib studies, will be presented in poster and e-poster sessions at the European Hematology Association (EHA) 21st Annual Congress, which is taking place from June 9-12 in Copenhagen.
The cerdulatinib ASCO abstract is available at abstracts.asco.org and the EHA abstracts are available at http://bit.ly/1U852D2. Details regarding the poster and e-poster presentations, which will include additional data not available in the abstracts, follow.
ASCO Annual Meeting 2016
- Abstract Title (abstract #7557/poster board #113): Cerdulatinib (PRT062070): A dual SYK/JAK inhibitor in patients with relapsed/refractory b-cell malignancies -- Pharmacokinetic and pharmacodynamic outcomes with twice-daily (BID) vs once-daily (QD) dosing
- Presenting Author: Paul A. Hamlin, M.D., medical oncologist, Memorial Sloan Kettering Cancer Center
- Poster Session Title: Hematologic Malignancies – Lymphoma and Chronic Lymphocytic Leukemia
- Poster Presentation Date and Time: Monday, June 6, 8:00-11:30 a.m. Central Time
- Location: McCormick Place, Hall A
EHA 21st Congress
- Abstract Title (abstract #LB2252): Phase 1 final results and Phase 2a dose selection for cerdulatinib (PRT062070), a dual Syk/JAK inhibitor in patients with relapsed/refractory B-cell malignancies
- Session Title: Chronic lymphocytic leukemia and related disorders -- Clinical
- E-poster Presentation Date and Time: Friday, June 10, 9:30 a.m.-Saturday, June 11, 7 p.m. CEST
- E-Poster Location: Bella Center, Hall H
- Abstract Title (abstract #E1017): Combined SYK and JAK inhibition by cerdulatinib induces apoptosis in CLL and overcomes resistance to ibrutinib
- Session Title: Chronic lymphocytic leukemia and related disorders -- Biology
- E-poster Presentation Date and Time: Friday, June 10, 9:30 a.m.-Saturday, June 11, 7 p.m. CEST
- Location: Bella Center, Hall H
- Abstract Title (abstract #P590): The SYK/JAK inhibitor cerdulatinib shows promising in vitro activity in chronic lymphocytic leukemia
- Session Title: Genomic complexity in CLL
- Poster Presentation Date and Time: Saturday, June 11, 5:30-7:00 p.m. CEST
- Location: Poster Area, Hall H
About Portola Pharmaceuticals, Inc.
Portola Pharmaceuticals is a biopharmaceutical company developing product candidates that could significantly advance the fields of thrombosis and other hematologic diseases. The Company is advancing three programs, including betrixaban, an oral, once-daily Factor Xa inhibitor; AndexXa™ (andexanet alfa), a recombinant protein designed to reverse the anticoagulant effect in patients treated with an oral or injectable Factor Xa inhibitor; and cerdulatinib, a Syk/JAK inhibitor in development to treat hematologic cancers. Portola's partnered program is focused on developing selective Syk inhibitors for inflammatory conditions. For more information, visit www.portola.com and follow the Company on Twitter @Portola_Pharma.